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Abstract
Background: Experimental studies indicate that gamma linolenic acid (GLA) and docosahexaenoic acid (DHA) may
inhibit glioma cells growth but effects of oral consumption of these fatty acids on brain tumor fatty acid composition have
not been determined in vivo.
Methods: GLA oil (GLAO; 72% GLA), DHA oil (DHAO; 73% DHA) were fed to adult wistar rats (1 mL/rat/day) starting
one week prior to C6 glioma cells implantation and continued for two weeks after implantation. Control group were fed
same amount of high linoleic acid safflower oil (74–77% linoleic acid). Fatty acid composition of tumor samples was
determined in a set of 8–12 animals in each group and serum fatty acid in 6 animals per each group. Gene expression of
tumor fatty acid binding protein 7 (FABP7), epidermal growth factor receptor (EGFR), peroxisome proliferator activated
receptor γ (PPAR-γ) and retinoid × receptor-α (RXR-α) were determined in a set of 18 animals per group.
Results: DHAO feeding increased EPA of brain tumors and decreased ratio of n-6/n-3 fatty acids. Serum levels of EPA
were also increased in DHAO group. A similar trend in serum and tumor levels of DHA were observed in DHAO group
but it did not achieve statistical significance. GLAO increased serum concentration of GLA but had no significant effect
on tumor GLA or dihomo-gamma linolenic acid (DGLA) concentrations. Gene expression of FABP7 was up-regulated in
tumors of DHAO group but no other significant effects were observed on EGFR, PPAR-γ or RXR-α expression, and
expression of these genes in tumors of GLAO were not different from SFO group.
Conclusion: Dietary supplementation of DHA containing oil could be an effective way to increase levels of long chain
n-3 fatty acids in brain tumors and this increase may be mediated partly by up-regulation of FABP7 expression.
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Background
Polyunsaturated fatty acids (PUFAs) have diverse func-
tions in living cells and influence membrane composition
and function, eicosanoid synthesis, cellular signaling and
regulation of gene expression [1]. Experimental studies
have shown that supplementation of tumor cells with spe-
cific fatty acids may decrease tumor proliferation.
Gamma-linolenic acid (GLA), an n-6 fatty acid, and n-3
fatty acids such as eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA) have received considerable
attention due to their anti-tumor activity against many
tumor cell lines [2-4]. Previous in vivo and clinical studies
have reported that GLA infusion into the rat or human gli-
oma could be effective in decreasing tumor growth
[2,3,5,6]. Although effective, this method can not be
applied for majority of patients. Long chain PUFAs of n-3
fatty acid such as EPA and DHA has also been shown to
have anti-proliferative effect on glioma cells in vitro [7,8].
Dietary intake of GLA and n-3 fatty acids has been
explored in some animal model of prostate, breast and
colon cancers [4,9-12] but these fatty acids may not be as
effective in brain tumors since blood brain barrier can
limit their uptake by brain tumor cells. Since dietary
intake of PUFAs could influence normal brain structure
and biological function [13], it may also affect brain
tumor fatty acid composition and function. A few studies
with limited samples have compared fatty acid composi-
tion of human brain tumors with that of normal brain tis-
sue and have found that concentration of n-3 fatty acids,
especially DHA, are lower in gliomas than non-tumoral
brain tissues [14,15].
Uptake and transport of PUFAs across cellular membrane
occurs to some extend by passive diffusion and addition-
ally is facilitated by a number of membrane associated
and cytoplasmic proteins[16]. Fatty acid binding proteins
(FABPs) are thought to facilitate transport and intracellu-
lar trafficking of fatty acids [16]. FABP7 (brain fatty acid
binding protein) is a member of FABPs which is highly
expressed in glial cells and bind to long-chain PUFA with
high affinity [17,18]. Its expression in glioma cell lines
and brain tumor specimens has been reported [19,20].
Additionally, in human brain tumor specimens, FABP7
expression has been shown to be associated with epider-
mal growth factor receptor (EGFR) overexpression [21].
PPAR-γ and RXR-α are members of nuclear receptors that
have been shown to be activated by some PUFAs [22,23].
In vitro and in vivo studies demonstrated that ligands of
these receptors may be effective in reducing growth and
invasiveness of glioma cell lines [24,25].
Rat C6 glioma model has been proven to be useful for a
variety of studies related to brain tumor biology [26]. The
aim of this study was to investigate the effects of oral feed-
ing of oils containing high concentration of GLA, DHA or
linoleic acid on blood and tumor total fatty acid compo-
sition in rat C6 glioma model. In addition, we studied
effects of supplementation of these oils on gene expres-
sion of FABP-7, EGFR, RXR-α and PPAR-γ as molecular
targets of PUFAs through which PUFAs may influence
functions of glioma tumors.
Results
Serum and tumor sample fatty acid composition
Table 1 shows serum fatty acid levels of rats. Concentra-
tion of GLA significantly increased in GLAO group relative
to SFO (5.1 fold; p < 0.05) or DHAO (13.3 fold; p < 0.01)
groups. In DHAO group, EPA levels were much greater
than SFO (21.8; p < 0.01) or GLAO (27.1 fold; p < 0.01)
groups. In addition, sum of n-3 fatty acids were signifi-
cantly higher and ratios of arachidonic acid/DGLA+EPA
and n-6/n-3 were significantly lower in DHAO group
compared to the two other groups. Levels of DHA were
significantly higher in DHAO than GLAO (5.8 fold; p <
0.05) but the increase in DHAO did not achieve statistical
significance when compared to SFO group (2.8 fold, p
value = 0.10). Arachidonic acid levels and sum of n-6 fatty
acids were also lower in DHAO relative to SFO group (p <
0.01 and p < 0.05 respectively).
Table 2 shows fatty acid profile of rats' tumor tissues. Fatty
acid analysis was performed on 8 samples of SFO group
because one sample was lost during lipid extraction. The
EPA content in DHAO group was greater than SFO (6 fold;
p < 0.01) and GLAO (5.3 fold (p < 0.01), and sum of n-3
fatty acid levels were significantly higher in DHAO than
SFO (2.2 fold; p < 0.05) and GLAO (3 fold; p < 0.01)
groups. Ratios of Arachidonic acid/DGLA+EPA and n-6/n-
3 were lower in DHAO group compared to the two other
groups. Levels of GLA were not significantly different
between three groups but linoleic acid content decreased
in GLAO relative to SFO group (2.8 fold; p < 0.01). Similar
to serum, DHA levels were significantly higher in DHAO
relative to GLAO (2.8 fold; p < 0.05) but non-significantly
higher in DHAO than in SFO group (1.9 fold; p= 0.13).
Gene expression
Figure 1 shows relative expression ratio of FABP7, EGFR,
PPAR-γ and RXR-α in brain tumors of DHAO when com-
pared to SFO group. Only FABP7 expression was signifi-
cantly changed and up-regulated in DHAO group relative
to SFO (P < 0.05) and the other variation in gene expres-
sion were not significantly different.
Figure 2 shows relative expression ratio of genes in GLAO
group relative to SFO group. No significant differences in
expression of FABP7, EGFR, PPAR-γ or RXR-α were
detected in GLAO when compared to SFO group.Lipids in Health and Disease 2008, 7:45 http://www.lipidworld.com/content/7/1/45
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Discussion
Results of current study show that feeding of DHA con-
taining oil to rats could increase EPA content of their brain
tumors. We expected it to also increase DHA levels of
tumor tissues but DHA levels only increased relative to
GLAO group. However, the data did show a trend to
higher levels of DHA in tumors of DHAO group com-
pared to SFO group. Similar results observed in serum lev-
els of DHA in studied groups. Previous works have found
that fatty acids in ethyl ester form have lower digestive and
Table 1: Fatty acid levels of rat serum of SFO, GLAO and DHAO groups
Fatty acids Concentration in serum (μg/mL) one way ANOVA
SFO GLAO DHAO
Miristic Acid (C14:0) 19.46 ± 0.44 19.76 ± 0.56 21.17 ± 1.24 NS
Palmitic Acid (C16:0) 89.28 ± 19.99 51.26 ± 12.72 49.83 ± 9.39 NS
Stearic Acid (C18:0) 99.86 ± 22.20 72.89 ± 21.60 62.69 ± 14.81 NS
Arachidic Acid (C20:0) 2.06 ± 0.00 2.22 ± 0.15 2.76 ± 0.69 NS
Behenic Acid (C22:0) 11.27 ± 0.60 10.73 ± 0.15 11.38 ± 0.39 NS
Oleic Acid(C18:1, n-9) 55.56 ± 14.91 23.44 ± 8.19 30.49 ± 7.53 NS
11-Ecosenoic Acid(C20:1) 52.04 ± 30.86 84.67 ± 57.88 30.19 ± 25.44 NS
Nervonic Acid (C24:1) 5.72 ± 00.00 5.99 ± 0.27 5.72 ± 00.00 NS
Linoleic Acid(C18:2, n-6) 229.75 ± 79.27 61.40 ± 18.03 94.16 ± 32.64 NS
Gamma linolenic acid(C18:3, n-6) 11.46 ± 6.55a 59.34 ± 16.44b 4.46 ± 2.75a P < 0.01
11,14-Ecosadienoic Acid (C20:2, n-6) trace 0.54 ± 0.76 1.90 ± 1.27 NS
Dihomo-Gamma Linolenic Acid(C20:3, n-6) 2.65 ± 0.50 4.137 ± 0.84 2.71 ± 0.52 NS
Arachidonic Acid(C20:4, n-6) 234.42 ± 45.92a 151.13 ± 34.27ab 36.54 ± 8.68b P < 0.01
13,16-Docosadienoic Acid (DDA, C22:2, n-6) 6.21 ± 0.39 5.81 ± 0.22 6.00 ± 0.29 NS
Alpha-Linolenic Acid(C18:3, n-3) trace trace 0.26 ± 0.20 NS
11,14,17-Eicosatrienoic Acid (C20:3, n-3) 2.61 ± 0.04 2.61 ± 0.06 2.56 ± 0.01 NS
Eicosapentaenoic acid (C20:5, n-3) 3.28 ± 1.64a 2.60 ± 1.31a 70.51 ± 17.66b P < 0.001
Docosahexaenoic acid (C22:6, n-3) 38.27 ± 5.92ab 18.48 ± 4.22a 107.31 ± 37.62b P < 0.05
Arachidonic/Dihomo-Gamma Linolenic + Eicosapentaenoic 83.77 ± 48.46a 26.75 ± 3.25a 0.56 ± 0.09b P < 0.001
Sum of n-6 fatty acids * 484.47 ± 118.15a 282.36 ± 65.79ab 145.78 ± 41.41b P < 0.05
Sum of n-3 fatty acids§ 44.26 ± 6.10a 23.70 ± 5.42a 180.66 ± 53.10b P < 0.001
n-6 to n-3 Ratio‡ 10.38 ± 1.62a 11.84 ± 1.11a 0.85514 ± 0.07b P < 0.001
* Including C18:2, C18:3, C20:2, C20:3, C20:4, C22:2. § Including C18:3, C20:3, C20:5, C22:6. ‡ Ratio of sum of n-6 fatty acids to sum of n-3 fatty 
acids. Values are shown as mean ± S.E., n = 6 for each group. ANOVA: Analysis of variance. NS: not significant. Groups not sharing the same letters 
are significantly different (Post-hoc Tukey's test)Lipids in Health and Disease 2008, 7:45 http://www.lipidworld.com/content/7/1/45
Page 4 of 11
(page number not for citation purposes)
absorptive efficiency than triglycerides [27] but we do not
believe slower digestion or absorption of ethylated DHA
was the main cause of non-significant increase of serum or
tumor DHA because serum EPA concentration increased
in DHAO group. Since EPA content of feeding oil was very
low, apparent increase in EPA content of serum and
tumor might be due to retroconversion of DHA to EPA.
Retroconversion, a peroxisomal process involving one
cycle of β-oxidation, has been reported in the liver of rats
given a single dose of DHA [28] and in humans consum-
Table 2: Fatty acid levels of rat tumors of SFO, GLAO and DHAO groups
Fatty acids Concentration in tumors (μg/g) one way ANOVA
SFO GLAO DHAO
Miristic Acid(C14:0) 30.57 ± 4.22 35.51 ± 6.00 46.93 ± 9.13 NS
Palmitic Acid (C16:0) 1142.71 ± 284.20 1421.68 ± 302.96 1841.48 ± 408.66 NS
Stearic Acid (C18:0) 2131.56 ± 648.05 1593.07 ± 303.45 2236.11 ± 465.52 NS
Arachidic Acid (C20:0) 12.80 ± 5.74 16.38 ± 4.19 27.43 ± 7.49 NS
Behenic Acid (C22:0) 27.79 ± 5.71a 104.28 ± 37.76ab 211.62 ± 66.79b P < 0.01
Oleic Acid(C18:1, n-9) 1368.56 ± 284.52 1787.10 ± 409.95 2793.21 ± 688.84 NS
11-Ecosenoic Acid(C20:1) 237.95 ± 103.44 262.70 ± 61.21 228.70 ± 65.03 NS
Nervonic Acid (C24:1) 7.45 ± 1.73 31.07 ± 14.25 20.12 ± 10.90 NS
Linoleic Acid(C18:2, n-6) 423.02 ± 79.54a 148.69 ± 24.49b 259.145 ± 48.66ab P < 0.01
Gamma linolenic acid(C18:3, n-6) 13.10 ± 11.02 39.57 ± 11.93 32.15 ± 13.39 NS
11,14-Ecosadienoic Acid (C20:2, n-6) 80.29 ± 60.90 31.89 ± 11.76 32.38 ± 8.46 NS
Dihomo-Gamma Linolenic Acid(C20:3, n-6) 32.29 ± 8.95 55.91 ± 16.27 40.98 ± 13.11 NS
Arachidonic Acid(C20:4, n-6) 1034.95 ± 285.23 970.49 ± 163.15 724.44 ± 142.53 NS
13,16-Docosadienoic Acid (DDA, C22:2, n-6) 18.87 ± 9.49 25.23 ± 12.66 28.79 ± 8.49 NS
Alpha-Linolenic Acid(C18:3, n-3) trace trace 0.80 ± 0.40 NS
11,14,17-Eicosatrienoic Acid (C20:3, n-3) 7.50 ± 2.61 6.93 ± 1.88 10.74 ± 2.33 NS
Eicosapentaenoic acid (C20:5, n-3) 58.67 ± 16.49a 67.30 ± 15.79a 359.12 ± 87.63b P < 0.01
Docosahexaenoic acid (C22:6, n-3) 746.72 ± 289.75ab 507.61 ± 110.12a 1423.24 ± 329.32b P < 0.05
Arachidonic/Dihomo-Gamma Linolenic + Eicosapentaenoic 9.34 ± 2.22a 10.84 ± 2.07a 2.38 ± 0.46b P < 0.01
Sum of n-6 fatty acids * 1608.55 ± 302.03 1271.81 ± 208.86 1117.89 ± 187.10 NS
Sum of n-3 fatty acids§ 813.16 ± 301.04a 581.86 ± 121.50a 1793.92 ± 383.56b P < 0.01
n-6 to n-3 Ratio‡ 4.12 ± 1.41a 3.07 ± 0.73a 0.72 ± 0.09b P < 0.05
* Including C18:2, C18:3, C20:2, C20:3, C20:4, C22:2. § Including C18:3, C20:3, C20:5, C22:6. ‡ Ratio of sum of n-6 fatty acids to sum of n-3 fatty 
acids. Values are shown as mean ± S.E., n = 8 for SFO group, n = 12 for GLAO group, and n = 9 for DHAO group. ANOVA: Analysis of variance. 
NS: not significant. Groups not sharing the same letters are significantly different (Post-hoc Tukey's test)Lipids in Health and Disease 2008, 7:45 http://www.lipidworld.com/content/7/1/45
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ing DHA [28,29]. In this study, serum concentration of
EPA increased in rats given DHAO which implicate retro-
conversion might have occurred in peripheral tissues such
as liver [30,31].
Serum levels of arachidonic acid decreased in DHAO rel-
ative to SFO group but decrease in tumor arachidonic acid
of DHAO group did not reach to level of significance.
DGLA, arachidonic acid and EPA are precursors for series
1, 2 and 3 of prostanoids respectively. Increase in EPA lev-
els and decrease in arachidonic acid/DGLA+EPA levels in
DHAO group could influence balance of prostaglandins
and leukotriens produced in tissue toward less inflamma-
tory eicosanoids [9,10,32]. In addition, decrease in ratio
of n-6/n-3 fatty acids in DHAO group indicate that con-
sumption of DHA may results in reciprocal replacement
of n-6 by n-3 fatty acids in tumor. In DHAO group, levels
of behenic acid (C22:0) increased, the origin or impor-
tance of this increase is not known.
Serum levels of GLA in GLAO group increased but no sig-
nificant increase in GLA levels of tumor tissues of GLAO
group were observed. The lack of increase in the GLA level
of tumor indicate that it may not have high uptake by
brain tumors or it may has been converted to longer
chained fatty acids in the tissue. In an study on male rats,
consumption of diet containing borage oil (comprised of
21% GLA and 35.8% linoleic acid) for two weeks
increased serum GLA, DGLA and arachidonic acid levels
and brain DGLA and arachidonic acid levels relative to
Expression ratio of genes in DHAO group Figure 1
Expression ratio of genes in DHAO group. Supplementation of DHAO increased gene expression of brain tumors FABP7 
of rats relative to SFO group (p < 0.05). Log2 scale of expression ratios and singnificancy were calculated by REST, using beta-
actin and GAPDH as reference genes and tumor samples of SFO group as control group and amplification efficiencies were 
considered in the analysis. Each value is mean ± S.E. of eighteen determination performed on separate animals.
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corn oil diet (brain GLA concentrations were not deter-
mined) [33]. In our study, neither serum nor brain tumor
concentration of DGLA did not increased significantly,
although a trend toward higher level of DGLA observed in
GLAO group. In another study on neonatal rats, addition
of 2.9 g GLA/100 g to a formula with low level of DHA
and feeding it for about two weeks had no significant
effects on DGLA and arachidonic acid levels of rat's fore-
brain but increased C22: 4 n-6 (adrenic acid) level of
brain [34]. We did not measure C22:4 n-6 levels in tumor
or serum of rats but tumor and serum levels of DHA in
GLAO group were slightly lower than SFO group and it
can be speculated that some GLA had been converted to
C22:4 n-6 and this fatty acid had replaced some DHA of
tumors.
A number of pathways have been suggested as potential
contributors to brain PUFA accretion [13]. Blood-brain
barrier functions to selectively transport long chained
PUFAs into the brain and facilitated transport by FABP7
may be one of the mechanism for this transport [13].
Recombinant FABP7 has high binding affinity for PUFAs
than saturated and monounsaturated fatty acids [17,35]
and among PUFAs, it exhibits higher affinity for n-3
PUFAs such as DHA and EPA [36]. In fact, binding affinity
of DHA to FABP7 is the highest reported among FABPs/
Expression ratio of genes in GLAO group Figure 2
Expression ratio of genes in GLAO group. Supplementation of GLAO had no significant effects on gene expression of 
EGFR, FABP7, PPAR-γ and RXR-α relative to SFO group. Log2 scale of expression ratios and singnificancy were calculated by 
REST, using beta-actin and GAPDH as reference genes and tumor samples of SFO group as control group and amplification effi-
ciencies were considered in the analysis. Each value is mean ± S.E. of eighteen determination performed on separate animals.
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ligand interaction [17]. Increase of n-3 fatty acid content
of brain tumor tissues in present study accompanied by
increase in mRNA levels of FABP7. In addition to their
effects on fatty acids transport, FABPs have been shown to
influence cellular growth and differentiation [37-39].
FABP7 expression in normal and breast tumor biopsies
was associated with mammary gland differentiation and
its overexpression in human breast cancer cells induced
differentiation [40]. In brain tumor specimens, expression
of FABP7 in primary glioblastoma was inversely associ-
ated with survival in a specific age group [20] and nuclear
but not cytoplasmic FABP7 protein was associated with
EGFR overexpression and shorter survival in glioblastoma
patients [21]. Study of human glioma cell lines indicate
that FABP7 mRNA and protein expression were positively
correlated with glial fibrilary acidic protein which is a
marker of differentiation of astrocytes [19]. Transfection
of FABP7 to FABP7 negative glioma cells decreased prolif-
eration and cell transformation and increased cell differ-
entiation and migration properties of cells, and FABP7
depletion in FABP7 positive glioma cells had no effect on
proliferation but decreased migration and resulted in
more transformed phenotype [41]. In our study, although
DHAO feeding increased FABP7 mRNA levels of rat's
brain tumors, it did not affect EGFR expression. Studies on
human breast tumor cells have shown that DHA and EPA
could actually decrease membrane lipid raft EGFR protein
level [42] and mediate part of growth inhibitory effects of
DHA on tumor cells [40]. FABPs may also bind PUFAs
and decrease their availability to intracellular oxidative
pathways [43,44]. Since long-chained PUFAs decrease
tumor proliferation by increasing free radical production
[45-47], increase in FABP7 expression of glioma following
DHA supplementation could reduce prooxidant effect of
DHA in tumors and consequently reduce their anti tumor
effects. This hypothesis could be explored in future stud-
ies.
Since PUFAs are natural ligands of RXRα and PPARγ
[22,23], effects of DHAO or GLAO supplementation on
gene expression of these two receptors in rat glioma
tumors were explored. When compared to SFO, neither
DHAO nor GLAO had any significant up or down-regula-
tory effects on expression of these receptors. One of possi-
ble reasons for this observation is large variability of gene
expression data and another reason may be short-term
intervention of this study. In an study, feeding of fish oil
or corn oil to rats increased colon mucosa RXRα and
PPARγ mRNA of fish oil group at week 16 but had no sig-
nificant effects at week 10 [48]. Since in the present study,
implantation of C6 cells to rat's brain caused some mor-
tality after 2 weeks, rats were sacrificed at week 2. Because
of smallness of developed tumors, we analyzed tumor
fatty acids and gene expression in two separate sets of ani-
mals in each intervention group and this was another lim-
itation of the current study.
Conclusion
Supplementation of DHA containing oil could increase
long chain n-3 fatty acid content of brain tumors and part
of this increase may be mediated by increase in expression
of FABP7. Short-term oral consumption of GLA may not
be an effective way to increase GLA or DGLA concentra-
tions of brain tumors. Since previous studies have found
that enriching tumors with long-chain n-3 fatty acids
could have beneficial effects on the treatment of tumors
[49], results of present study implicate that oral supple-
mentation is an effective way to increase levels of these
fatty acids in brain tumors.
Methods
Materials
Docosahexaenoic acid ethyl ester oil (containing 80%
DHA) and gamma-linolenic acid ethyl ester oil (contain-
ing 72% GLA) were obtained from Minami Nutrition
Company (Edegem, Belgium). C6 rat brain glioma cell
line was purchased from national cell bank of Iran. Alpha
cellulose, Casein, L-Cystin, Cholin bitartrate, tert-butyl
hydroquinone, Supelco 37 component fatty acid methyl
ester mix, Dulbecco's modified Eagle's Medium (DMEM),
Penicillin, streptomycin and Hamilton syringe were
obtained from Sigma (Germany, GmbH). Fetal calf serum
and trypsin-EDTA were purchased from Invitrogen (Ger-
many, GmbH). RNA Latter, RNeasy mini kit, QuantiTec
Reverse transcription kit and Quantifast SYBR green kit
were from Qiagen Company (Germany, GmbH). Primers
were synthesized by BIONEER (Korea).
Animals and experimental groups
Female virgin random-bred wistar rats, weighing 200 to
240 g were obtained from Iran Pasteur institute and were
studied under the protocol approved by Tehran University
of Medical Sciences Animal Research Committee. Rats of
each group were housed in different separate cages under
temperature of 20 ± 4°C and a 12-h light-dark cycle with
free access to food and water.
Since developed tumors from injected C6 cells are small,
we decided to determine fatty acid composition in one set
of rats and mRNA level in another set of rats in each
group. Animals were randomly divided into three groups
of twenty seven for SFO, twenty seven for DHAO and
thirty for GLAO groups. A set of nine rats for SFO and
DHAO and 12 rats for GLAO were randomly selected for
analysis of fatty acid composition and remaining animals
were assigned for mRNA expression quantitation. A low
fat diet (table 3) prepared twice weekly, kept at 4°C and
was given to the rats of all groups. Vitamin and mineral
mixes used for diet preparation formulated according to
AIN93M vitamin and mineral mix [50]. Experimental oils
were fed to the animals through a gavage needle at the
dose of 1 ml/rat/day. Safflower oil with high linoleic acid
(SFO group) and gamma-linolenic acid ethyl ester rich oilLipids in Health and Disease 2008, 7:45 http://www.lipidworld.com/content/7/1/45
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(GLAO group) and docosahexaenoic acid rich oil
(DHAO) were fed to rats of each groups (table 4). To
equalize DHA content of DHAO to the level of GLA in
GLAO, 85 volume of DHA 80% was mixed with 15 vol-
ume of safflower oil. Diet and oil feeding started one week
prior to tumor implantation and continued for 2 weeks
after implantation when animals were anesthetized by
chloroform inhalation, non-fasting blood was taken from
heart and whole brain was extracted, put in RNA Later for
RNA extraction or its tumor immediately isolated and
snap freezed in liquid nitrogen and kept at -70°C until
fatty acid analysis. Brains in RNA later were kept at 4°C for
3–5 days until its tumor area isolated for RNA extraction.
Tumor implantation
C6 rat glioma cell line was grown in DMEM supple-
mented with 10% (vol/vol) fetal calf serum, 100 mg/ml
streptomycin and 100 U/ml penicillin in a 5% CO2
atmosphere. At the day of tumor implantation, 85–90%
confluent cells were trypsinized, washed by DMEM,
counted by hemocytometer and resuspended in DMEM at
density of 20 × 106/ml. Animals were anesthetized by an
intraperitoneal injection of ketamin 80 mg/kg and xyla-
zine 2 mg/kg prior to surgery and the anesthetized rat was
placed in a stereotactic head frame where head was
prepped with povidone iodide (10%) and a midsaggital
scalp incision was made and after retracting periosteom, a
hole was drilled at anteroposterior +3.0 mm, right -2.0 rel-
ative to bregma. Tumor cells were injected using a 22 gage
Hamilton syringe mounted on the stereotactic holder at
the depth of 6 mm. A volume of 5 μL of cell suspension,
containing 100 × 103 cells was injected in 3 minutes and
the needle was left in place for 5 minutes. After needle
withdrawal, the hole was sealed with sterile bone wax and
the incision closed with 4-0 suture.
Fatty acid extraction and gas chromatography
Fatty acid extraction were carried out by method of Chris-
tie [51] with some modifications. Tumor tissue or serum
was homogenized in chloroform: methanol (2:1 vol/vol
containing 80 mg/L Butylated Hydroxy Toluene) by a
glass homogenizer on ice (or vigorous shacking in a glass
tube for serum sample), centrifuged and supernatant was
taken into a tube. Homogenization repeated twice for the
remaining pellet. Normal saline was added to the com-
bined supernatants, shacked vigorously and were allowed
to phase separate. The upper layer was drawn off by aspi-
ration followed by addition of methanol: saline (1:1 vol/
vol) to the lower phase and the washing procedure was
repeated. Extracted lipids were dried under a stream of
nitrogen. The dried lipids were soaponified by the method
described previously[52]. Soaponified fatty acids were
transesterified by boron trifluoride (BF3) in methanol.
BF3 was added to the sample and incubated at 100°C in
a water bath for an hour. After cooling to room tempera-
ture, hexane, HCL and water was added, shacked vigor-
ously, centrifuged and upper phase was taken into a new
tube and dried with nitrogen. Before injecting to the
instrument, methanol and ethylated margaric acid (as an
internal standard) were added to samples and fatty acids
methyl esters (FAMEs) measured by gas chromatography.
A capillary column with 60 m length, 0.25 mm internal
diameter and 0.2 μM film thickness on a HP 6890 GC
equipped with Flame Ionization Detector was used to
qualify and quantify FAMEs. The initial column tempera-
ture was set at 195°C for 2 min, increased to 205°C by
2°C/min, then to 214°C by 1°C/min, then to 240°C by
15°C/min and held for 10 min. Helium was used as the
carrier gas at an initial flow rate of 1 mL/min for 8 min,
increased to 1.3 ml/min for 4.2 min and then increased to
1.9 ml/min. The detector temperature was set at 300°C
and injector temperature at 250°C. Fatty acids methyl
esters were identified by comparison with retention times
of Supelco 37 component FAME mix standard. We
focused on PUFAs in chromatogram and excluded short
and medium chain saturated fatty acids from chromato-
gram. Different concentrations of FAME mix with added
ethylated margaric acid were injected to GC to obtain
standard curve for each fatty acid. The peak area of a given
fatty acid divided to peak area of internal standard (ethyl-
ated margaric acid) was calculated and with regard to
standard curve, concentrations of fatty acids in tissue or
serum were estimated.
Table 3: Composition of low fat diet
Ingredients g/kg diet
Corn starch 645
Casein 140
Sucrose 100
Soybean oil 15
Alpha-cellulose 50
Mineral Mix * 35
Vitamin Mix * 10
L-Cystine 1.8
Choline Bitartrate 2.5
Tert-butyl hydroquinone 0.003
*-Formulated according to AIN93M vitamin and mineral mix [50]Lipids in Health and Disease 2008, 7:45 http://www.lipidworld.com/content/7/1/45
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QRT-PCR
Total RNA was extracted from tumor samples using RNe-
asy mini kit as per manufacturer's instructions. RNA
extract was analyzed spectrophometrically to determine
purity and concentration and electrophoresd to check
integrity. cDNA was synthesized from extracted RNA
using QuantiTect Reverse Transcription Kit in which
genomic DNA is removed by genomic DNA wipeout
buffer before RT reaction. Synthesized cDNA was ana-
lyzed spectrophotometrically to determine concentration
and stored in aliquots at -20°C until use.
Table 5 summarized primers used in this study. Primer
sequence for PPARγ [53], EGFR [54] and RXRα [55] and
FABP7 [56] were obtained from previous studies. Primer
sequence for Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) and Beta-Actin were designed by PerlPrimer
[57] and OligoAnalyzer (Integrated DNA Technologies),
and the specificity of the sequences was analyzed by the
BLAST database. Except for GAPDH, the primers were
either located in different exons or across exon-exon
boundaries.
Table 4: Major fatty acids of oils1
Fatty acids (%) Oil source
High linoleic acid safflower oil 
(SFO)2
Gamma-linolenic acid oil (GLAO) Docosahexaenoic acid oil 
(DHAO)3
Oleic acid 11 0 1.6
Linoleic acid 74–77 26 11.5
Gamma-linolenic acid 0 72 0
Docosahexaenoic acid 0 0 73
1 Refers to fatty acids composition as reported by the supplier.
2 High linoleic President's Choice Safflower Oil
3 Eighty-five volume of DHA 80% Ethyl Ester were mixed with 15 volume of safflower oil to reduce DHA content of oil to 72–74%
Table 5: Primers for Real-time RT-PCR
Gene Primer orientation Neucleotide sequence Amplicon (bp) NCBI Accetion number
Beta-actin forward 5-CCCTAGACTTCGAGCAAGAG-3 155 NM_031144.2
reverse 5-GGATTCCATACCCAGGAAGG-3
EGFR forward 5-CCCACAGCAAGGCTTCTTCA-3 119 NM_031507.1
reverse 5-CACGGCAGCTCCCATTTCTA-3
FABP7 forward 5-ATGGAGACAAGCTCATTCATGTG-3 134 NM_030832
reverse 5-TGCCTTTTCATAACAGCGAACA-3
GAPDH forward 5-GTGCTGAGTATGTCGTGGAGTCTA-3 144 NM_017008.3
reverse 5-TCTCGTGGTTCACACCCATCAC-3
PPARγ forward 5-CTGACCCAATGGTTGCTGATTAC-3 80 NM_013124.2
reverse 5-GGACGCAGGCTCTACTTTGATC-3
RXRα forward 5-GAGGACATGCCTGTAGAGAAGATT-3 126 NM_012805.2
reverse 5-ACAGATGTTGGTAACAGGGTCATT-3Lipids in Health and Disease 2008, 7:45 http://www.lipidworld.com/content/7/1/45
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Real-time PCR was performed on a Corbett RotorGene
6000 (Corbett Research, Australia) using Quantifast
SYBR-green PCR Master Mix. The PCR reactions contained
5 μL of 2X SYBR master mix, 250 ng of cDNA, and 300 nM
of GAPDH, Beta-Actin, FABP7, RXR-α primers or 1 μM of
EGFR or PPARγ primers in total volume of 10 μL and sam-
ples were run in duplicate. Thermal cycler conditions
included holds for 5 minutes at 95°C, followed by 43
cycles of 15 seconds at 95°C and 40 seconds at 60°C.A
melting curve analysis was performed for each reaction
with 62–95°C ramp. No template control (NTC) consist-
ing of H2O for target and reference genes were included in
each run. Initially, electrophoresis on agarose gel were
also performed to demonstrate that qRT-PCR yielded a
unique band. The amplification efficiencies of target and
reference genes were determined by dilution method,
using 3 concentrations of cDNAs of 100, 150 and 250 ng
for each gene. Three standard curve of three combined
cDNAs of samples were drawn separately and mean effi-
ciency for each gene determined and used for data analy-
sis by Relative expression software tool (REST) [58]. Beta-
actin and GAPDH served as reference genes.
Statistical analysis
Concentrations of fatty acids in serum and tissue tested for
normality with non-parametric Kolmogorov-Smirnov
and variables with no normal distribution were trans-
formed to Lg10 values. One-Way ANOVA was carried out
to analyze fatty acids concentrations with post-hoc Tukey's
multiple comparisons. Two-sided P values < 0.05 were
considered significant. The statistical significance of QRT-
PCR data calculated using the relative expression software
tool which uses pair wise fixed reallocation randomiza-
tion test. The level of probability was set at P < 0.05 as sta-
tistically significant.
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